KP INSIDER NEWS ALERT: Slow Uptake of Alzheimer’s Drug Leqembi Raises Concerns
Leqembi, the first drug shown to slow the progression of Alzheimer’s disease, has been on the U.S. market for over a year. However, sales have been slow and major hospital systems have taken months to start using it.
Some insurers have even rejected coverage for the drug, causing additional challenges for patients looking to access the treatment. Doctors are also acknowledging that some patients may hesitate to take Leqembi due to its limited impact and potential side effects, such as brain swelling and bleeding.
Despite its potential benefits, concerns about the drug have been raised as health systems work on setting up systems to deliver Leqembi effectively. Insurance coverage for the drug, infusions, and scans is still being navigated, leading to delays and challenges for some patients who are eager to start treatment.
Researchers are continuously working on potential treatments for Alzheimer’s, but there is still much to learn about the disease. In the meantime, the slow uptake of Leqembi has shed light on the complexities of managing Alzheimer’s and the importance of addressing the challenges associated with its treatment.
As the medical community continues to navigate the landscape of Alzheimer’s treatment options, it is crucial to stay informed and advocate for improved access to innovative therapies like Leqembi. Stay tuned to KP INSIDER for more updates on the latest developments in Alzheimer’s research and treatment.
“Social media scholar. Reader. Zombieaholic. Hardcore music maven. Web fanatic. Coffee practitioner. Explorer.”